Luxturna (Voretigene Neparvovec-rzyl)
|Prognosis Snapshot: November 2016|
|Proposed Use||Gene therapy for treatment of vision loss due to RPE65 gene mutation|
|Regulatory Status||Phase I/II Trials Complete||Phase III Trials in Progress||Phase III Trials Published||FDA Filing Complete||FDA Approved|
|Estimated Commercial Availability||Unable to Determine||>2 years||1 to 2 years||<6 months||Currently Available|
Download the report to continue reading...